Claims for Patent: 9,511,084
✉ Email this page to a colleague
Summary for Patent: 9,511,084
Title: | Compositions including triciribine and methods of use thereof |
Abstract: | This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. |
Inventor(s): | Cheng; Jin Q. (Tampa, FL), Sebti; Said M. (Tampa, FL) |
Assignee: | University of Florida (Tampa, FL) |
Application Number: | 14/514,311 |
Patent Claims: | 1. A method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising: a. confirming whether the subject has a tumor or
cancer that overexpresses AKT kinase and administering to said subject: i. at least one compound of formula I selected from the group consisting of the following compounds: ##STR00025## wherein each R.sub.2', R.sub.3', and R.sub.5' is independently
hydrogen; optionally substituted phosphate or phosphonate; mono-, di-, or triphosphate; acyl; lower acyl; alkyl; lower alkyl; amide; sulfonate ester; alkyl sulfonate ester; arylalkyl sulfonate ester; sulfonyl; methanesulfonyl; benzyl
sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; optionally
substituted arylsulfonyl; a lipid; phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I; wherein R.sub.2', R.sub.3' or
R.sub.5' is independently H or mono-, di- or tri-phosphate; wherein R.sup.x and R.sup.y are independently hydrogen; optionally substituted phosphate; acyl; lower acyl; amide; alkyl; lower alkyl; aromatic; polyoxyalkylene; polyethyleneglycol;
optionally substituted arylsulfonyl; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and wherein R.sub.1 and R.sub.2 each are independently H, optionally
substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or
aralkylsulfonyl; ii. trastuzumab or a salt thereof; and iii. a pharmaceutically acceptable carrier.
2. The method of claim 1, wherein the compound of formula I is triciribine phosphate. 3. The method of claim 1, wherein the compound of formula I is present in an amount of at least 20 mg/m.sup.2. 4. The method of claim 1, wherein the compound of formula I is present in an amount of at least 10 mg/m.sup.2. 5. The method of claim 1, wherein the administration is parenteral administration. 6. The method of claim 1, wherein the parenteral administration is intravenous administration. 7. The method of claim 1, wherein administration is oral administration. 8. The method of claim 1, suitable for topical administration. 9. The method of claim 1, wherein the trastuzumab or salt thereof is present in an amount from about 1 mg to about 1000 mg. 10. The method of claim 1, wherein the trastuzumab or salt thereof is present in an amount from about 100 mg to about 500 mg. 11. The method of claim 1, wherein the trastuzumab or salt thereof is present in an amount from about 200 mg to about 450 mg. 12. The method of claim 1, wherein the trastuzumab or salt thereof is present in an amount of about 440 mg. 13. The method of claim 1, wherein the administration of a compound of formula I and trastuzumab or a salt thereof is concurrently administered. 14. The method of claim 1, wherein the administration of a compound of formula I is following by the administration of trastuzumab or a salt thereof. 15. The method of claim 1, wherein the administration of trastuzumab or a salt thereof is followed by the administration of a compound of formula I. |
Details for Patent 9,511,084
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2024-03-29 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2024-03-29 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2024-03-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.